source
- Vanda pauses social anxiety program after Phase 3 trial misses endpoint in womenVanda Pharmaceuticals announced Wednesday that it is halting development of its social anxiety disorder candidate after a late-stage trial did not achieve its primary goal. The experimental drug,…
- OrbiMed raises $3 billion, its biggest Asian fund yet, to boost biotech investments worldwideOrbiMed announced it has closed a $3 billion fundraising round, the largest ever for its Asia‑focused vehicle. The capital will be used to make new growth‑equity and venture investments in biotech…